Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1305-1309
Published online before print June 20, 2002, doi: 10.1161/01.ATV.0000026614.72957.E7
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
22/8/1305    most recent
01.ATV.0000026614.72957.E7v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sata, M.
Right arrow Articles by Walsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sata, M.
Right arrow Articles by Walsh, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Restenosis
Right arrow Genetically altered mice
Right arrow Smooth muscle proliferation and differentiation
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1305.)
© 2002 American Heart Association, Inc.


Vascular Biology

Mouse Genetic Evidence That Tranilast Reduces Smooth Muscle Cell Hyperplasia via a p21WAF1-Dependent Pathway

Masataka Sata; Akihiro Takahashi; Kimie Tanaka; Miwa Washida; Nobukazu Ishizaka; Junya Ako; Masao Yoshizumi; Yasuyoshi Ouchi; Takahiro Taniguchi; Yasunobu Hirata; Mitsuhiro Yokoyama; Ryozo Nagai; Kenneth Walsh

From the Department of Cardiovascular Medicine (M.S., K.T., M.W., N.I., Y.H., R.N.) and the Department of Geriatric Medicine (J.A., M.Y., Y.O.), University of Tokyo Graduate School of Medicine, Tokyo, Japan; the Division of Cardiovascular and Respiratory Medicine (A.T., T.T., M.Y.), Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; and the Division of Cardiovascular Research (M.S., A.T., K.W.), St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Mass.

Correspondence to Dr Masataka Sata, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail msata-circ{at}umin.ac.jp

Objective— N-(3'4'-dimethoxycinnamoyl)-anthranilic acid (tranilast) is a drug that has been shown to reduce the incidence of restenosis after angioplasty in middle-scale clinical trials. Despite clinical interest in this drug, the pharmacological actions of tranilast remain relatively unexplored at a molecular level.

Methods and Results— We evaluated the effects of tranilast on vascular smooth muscle cell (VSMC) proliferation in wild-type mice and in mice lacking a cyclin-dependent kinase inhibitor, p21WAF1 (p21). Tranilast potently inhibited the proliferation of VSMC cultures derived from wild-type mice, but VSMCs derived from p21-deficient (p21-/-) mice were unaffected by this treatment. In a mouse femoral artery model of vascular injury, tranilast administration to wild-type mice led to an upregulation of p21 expression and a decrease in the number of proliferating VSMCs, as determined by immunostaining for proliferating cell nuclear antigen. In contrast, tranilast had no effect on the number of proliferating cell nuclear antigen–positive cells in the injured arteries of p21-/- mice. Administration of tranilast significantly reduced the neointimal VSMC hyperplasia in wild-type mice at 4 weeks but had no effect on lesion formation in p21-/- mice.

Conclusions— Our findings provide genetic evidence that tranilast inhibits intimal hyperplasia via a p21-dependent pathway, an activity that may contribute to its efficacy in the prophylactic treatment of postangioplasty restenosis.


Key Words: pharmacology • genetically altered mice • smooth muscle cells • restenosis • proliferation




This article has been cited by other articles:


Home page
CirculationHome page
D.J.W. Evans, L.E. Jackman, J. Chamberlain, D.J. Crosdale, H.M. Judge, K. Jetha, K.E. Norman, S.E. Francis, and R.F. Storey
Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis
Circulation, January 6, 2009; 119(1): 116 - 122.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. S. Santiago, H. Ishii, S. Shafi, R. Khurana, P. Kanellakis, R. Bhindi, M. J. Ramirez, A. Bobik, J. F. Martin, C. N. Chesterman, et al.
Yin Yang-1 Inhibits Vascular Smooth Muscle Cell Growth and Intimal Thickening by Repressing p21WAF1/Cip1 Transcription and p21WAF1/Cip1-Cdk4-Cyclin D1 Assembly
Circ. Res., July 20, 2007; 101(2): 146 - 155.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. S. Schwartz, N. A. Chronos, and R. Virmani
Preclinical restenosis models and drug-eluting stents: Still important, still much to learn
J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Sata and R. Nagai
Origin of Neointimal Cells in Autologous Vein Graft
Arterioscler Thromb Vasc Biol, July 1, 2004; 24(7): 1147 - 1149.
[Full Text] [PDF]